Peapack Gladstone Financial Corp Buys 1,683 Shares of Zoetis Inc. (NYSE:ZTS)

Peapack Gladstone Financial Corp grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 78,687 shares of the company’s stock after buying an additional 1,683 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Zoetis were worth $12,821,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC raised its position in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its position in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the period. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the period. Murphy & Mullick Capital Management Corp acquired a new stake in Zoetis in the fourth quarter valued at $44,000. Finally, Asset Planning Inc bought a new position in Zoetis during the 4th quarter worth $58,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $151.76 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business’s fifty day moving average is $165.71 and its 200 day moving average is $173.26. The stock has a market cap of $67.96 billion, a P/E ratio of 27.74, a P/E/G ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 12-month low of $144.69 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.32%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ZTS shares. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Piper Sandler increased their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.